Ketamine vs MDMA Therapy: Which Psychedelic Treatment Fits You?

You've tried the standard treatments. Maybe several antidepressants, years of talk therapy, or both. Now you're researching alternatives, and two names keep appearing: ketamine and MDMA. The headlines blend together, both promising something different for people who haven't found relief through conventional approaches.

The critical difference between them comes down to access.

The bottom line: Ketamine treatment is legally available today for treatment-resistant depression through FDA-approved esketamine or off-label racemic ketamine. MDMA-assisted therapy was rejected by the FDA in August 2024 and currently has no approved clinical use, with access limited to clinical trials. If depression is your primary condition, ketamine is accessible now. If PTSD is your primary concern, current options include trauma-focused therapies like EMDR and cognitive processing therapy while MDMA remains unavailable.

One note before the comparison: this article covers therapeutic use under medical supervision, not recreational use. Both substances exist as street drugs, but therapeutic protocols involve controlled dosing, clinical screening, and professional support that change the safety picture entirely.

How Do Ketamine and MDMA Therapy Compare?

This table covers what matters most for your decision:

The research, mechanisms, and safety data behind these differences follow.

What Is Ketamine Therapy?

Ketamine was originally approved by the FDA in 1970 as an anesthetic. Researchers discovered its rapid antidepressant effects in the early 2000s, and it's been gaining ground in psychiatry ever since.

Today, ketamine therapy comes in several forms. The FDA has approved esketamine nasal spray (Spravato) for treatment-resistant depression (TRD) in 2019 and for major depressive disorder (MDD) with acute suicidal ideation in 2020, both in conjunction with an oral antidepressant. IV ketamine infusions remain off-label for psychiatric conditions but are widely used in specialized clinics. Sublingual ketamine tablets offer an at-home option with telehealth clinical support.

For people who've waited months for antidepressants to kick in, ketamine's speed is the draw. Unlike traditional medications that build up over weeks, it can begin working within hours, with response occurring within 24–72 hours in many cases.

What Is MDMA-Assisted Therapy?

MDMA-assisted therapy pairs the drug MDMA with intensive psychotherapy, designed specifically for chronic, severe PTSD. The MDMA serves as a catalyst for deeper trauma processing during therapy sessions. It lowers your defenses enough that difficult memories become approachable.

In clinical trials, the protocol involved three MDMA-assisted sessions spread over 12 weeks, with preparatory therapy before and integration sessions after each one. Each MDMA session lasted 8–12 hours with two trained therapists present throughout.

MDMA received FDA breakthrough therapy designation in 2017, and Phase 3 trial results published in 2021 were widely seen as promising. The FDA's independent advisory committee voted against approval in June 2024, and the FDA issued a complete response letter rejecting the application in August 2024. Key concerns included functional unblinding (participants could easily tell whether they'd received MDMA or placebo), potential selection bias, and questions about data integrity and the conduct of some trial sites. MDMA remains a Schedule I controlled substance with no approved medical use, and no resubmission timeline has been announced.

How Do They Work in the Brain?

These two treatments target fundamentally different brain systems, which explains why they show promise for different conditions.

Ketamine

Ketamine targets your brain's glutamate system rather than serotonin like traditional antidepressants. The mechanism works in stages:

Stage 1: Releasing the brake. Ketamine blocks NMDA receptors on inhibitory brain cells, removing the suppression that depression places on neural activity.

Stage 2: The glutamate surge. With that brake released, your brain releases glutamate, the primary signal that gets neurons communicating.

Stage 3: Growth factor release. The glutamate surge triggers production of brain-derived neurotrophic factor (BDNF), essentially fertilizer for brain cells.

Stage 4: New connections form. Within hours, new synaptic connections start forming in depression-relevant brain regions. Molecular Psychiatry research shows rapid increases in synaptic connectivity in the prefrontal cortex and hippocampus.

This neuroplasticity happens fast. The medication opens a window for change; what happens during that window determines how lasting the benefits become.

MDMA

MDMA works through an entirely different mechanism. It quiets your brain's fear center (the amygdala) while strengthening connections between emotion regulation circuits. The serotonin and oxytocin release creates a window where fear drops enough that you can approach traumatic memories without the overwhelming anxiety that normally makes you avoid them.

What Does Research Show About Effectiveness?

Ketamine for Depression

Multiple randomized controlled trials demonstrate ketamine's efficacy for treatment-resistant depression. Response rates range from 46–67% across studies, with one trial showing 67% response to ketamine versus 20% with placebo. A trial in the New England Journal of Medicine found ketamine performed comparably to electroconvulsive therapy (ECT), with 55.4% response for ketamine versus 41.2% for ECT.

The major limitation is duration. Without maintenance treatment, symptom relief often diminishes within several weeks. Lancet Psychiatry research places the typical window at 2–4 weeks. That's why ongoing treatment with therapeutic support matters.

MDMA for PTSD

Phase 3 trials published in Nature Medicine found that 71.2% of MDMA-assisted therapy participants no longer met PTSD diagnostic criteria after treatment, compared to 47.6% in placebo groups. The nightmares, hypervigilance, and emotional numbness had reduced enough that participants could function in ways they hadn't for years. The trial population had a mean PTSD duration of 16+ years, with 92.5% experiencing comorbid major depression.

Follow-up data suggest a majority of responders maintained substantial improvement at one year after just three sessions, though these durability findings are under scrutiny given the FDA's concerns about trial methodology.

How Do Safety Profiles Compare?

Safety is probably one of the bigger questions on your mind, especially if you're considering a treatment that involves a psychoactive substance.

Ketamine

Post-market surveillance shows serious adverse events are very rare, well under 1% in large analyses of supervised treatment. Common effects include temporary dissociation, dizziness, nausea, and brief blood pressure increases that typically resolve within 1–2 hours. Ketamine is contraindicated for people with uncontrolled high blood pressure, active psychosis, unstable heart disease, or history of ketamine abuse.

MDMA

MDMA produces more pronounced cardiovascular effects, including substantial increases in heart rate and blood pressure at therapeutic doses. Phase 3 trials reported that jaw clenching, muscle tension, and cardiovascular changes were very common in the MDMA groups, though no MDMA-related serious adverse events were reported. Longer-term and larger-scale safety data remain limited.

MDMA is contraindicated for people with heart conditions, uncontrolled hypertension, seizure disorders, or active psychosis. It also carries serotonin syndrome risk when combined with MAOIs or SSRIs. That's a significant practical concern, since many people researching MDMA therapy for PTSD are already taking antidepressants.

What Does Treatment Actually Feel Like?

During ketamine sessions, most people describe a dissociative experience where ordinary thinking patterns shift. Colors may appear more vivid, time perception changes, and you may feel a sense of floating or detachment from your body. Verbal conversation is limited during peak effects, which typically last 40–60 minutes. Many people report feeling lighter or more hopeful in the hours and days following treatment. Ketamine experiences vary, but knowing what to expect helps you prepare.

MDMA sessions (as studied in clinical trials) are quite different. Participants remained lucid and conversational throughout. Most describe a sense of emotional openness and lowered defensiveness, where the fear that normally surrounds traumatic memories quiets enough to talk about them directly, often for the first time.

Which Treatment Fits Your Situation?

Ketamine may be right for you if your main struggle is depression that hasn't responded to at least two different antidepressants, your symptoms are severe enough that waiting weeks for another medication feels unsustainable, and you can commit to ongoing maintenance treatment. You'll also need to be clear of the contraindications listed in the safety section above.

MDMA-assisted therapy may suit your situation when it becomes available if chronic, severe PTSD is your primary diagnosis and standard trauma treatments haven't helped. Until then, evidence-based options include trauma-focused therapies like EMDR and cognitive processing therapy, along with SSRIs like sertraline and paroxetine.

How Innerwell's At-Home Ketamine Therapy Works

If treatment-resistant depression brought you here, Innerwell offers at-home ketamine therapy that pairs medication with licensed therapeutic support. This isn't ketamine mailed to your door with minimal oversight.

The process:

1. Evaluation: A psychiatric clinician reviews your history, current medications, and past treatment responses to determine whether ketamine therapy is appropriate.
2. Delivery: Sublingual ketamine tablets arrive at your home through a licensed pharmacy with adult-signature verification.
3. Preparation and integration: Licensed psychotherapists guide intention-setting before each session and work with you to process insights afterward. The medication opens a door; therapy helps you walk through it.
4. Ongoing monitoring: Your care team tracks mood and symptoms and adjusts dosing and treatment plans based on your response.

Every Innerwell patient works with Master's and Doctoral level psychiatric clinicians and licensed psychotherapists, not unlicensed guides. Integration sessions are central to the treatment approach.

Pricing: Treatment plans start as low as $54 per session with insurance, with coverage available in California and New York. Self-pay options start at $83 per session.

Program outcomes: 87% of Innerwell patients report improvement within four weeks. After 10 weeks, depression symptoms drop by 69% and anxiety symptoms by 60%. Patients rate the program 4.7 out of 5.

If PTSD is your primary concern, Innerwell also offers EMDR therapy and trauma-focused talk therapy with licensed clinicians. For people with both depression and PTSD, ketamine therapy combined with trauma-focused approaches can address both conditions.

Take the free assessment to see if ketamine therapy might work for you.

Frequently Asked Questions

Can ketamine help with PTSD?

Ketamine shows promise for comorbid PTSD and treatment-resistant depression when depression is the primary target. The evidence base for PTSD specifically is still developing. For primary PTSD without significant comorbid depression, established trauma-focused therapies remain first-line options.

When will MDMA therapy become legal?

There's no announced timeline. The FDA's August 2024 rejection means the sponsor needs to conduct additional trials before resubmitting, which many commentators estimate will take years. If you're looking for access now, clinical trial participation through ClinicalTrials.gov may be an option, though eligibility criteria are strict and enrollment is limited.

What if I have both depression and PTSD?

Start by identifying which condition is more functionally impairing. If depression is primary or more severe, ketamine therapy may be appropriate. Innerwell's clinical team can evaluate that during your initial assessment. For primary PTSD, trauma-focused therapy approaches are recommended while MDMA-assisted therapy remains unavailable.

Can ketamine and MDMA be used together or sequentially?

There's no established clinical protocol for combining them, and this remains a research question rather than a treatment option. Some researchers are exploring sequential psychedelic-assisted therapy models, but no evidence-based guidelines exist yet.

What about psilocybin therapy?

Psilocybin is showing promise in clinical trials for treatment-resistant depression, with some Phase 2 results comparable to ketamine's. But like MDMA, it has no FDA approval for psychiatric use, and Phase 3 trials are still underway.